A period of high interest rates and economic headwinds have made it challenging for companies in Latin America to secure financing for transactions. Against this backdrop, businesses, dealmakers, and lenders have increasingly...more
The high yield bond markets in the US and Europe sprang back to life in Q1 2024, with issuance showing strong gains after a slow 2023.
US high yield bond issuance for Q1 2024 came in at US$68.6 billion, almost doubling...more
Lenders and borrowers in US leveraged finance markets have had to recalibrate pricing and issuance volume expectations in 2022 in the face of rising inflation and interest rates....more
Following a year of healthy activity, M&A deals in the pipeline are set to sustain leveraged finance issuance in the pharmaceutical, medical and biotech sector in the months ahead -
Lender appetite for exposure to the...more
2/9/2022
/ Acquisitions ,
Biotechnology ,
Borrowers ,
Capital Markets ,
Coronavirus/COVID-19 ,
Environmental Social & Governance (ESG) ,
Financial Services Industry ,
Global Market ,
Healthcare ,
High Yield Bonds ,
Lenders ,
Leveraged Loans ,
Mergers ,
Pharmaceutical Industry
Management teams and private equity (PE) sponsors have successfully deployed a range of liability management tools to steer companies through the COVID-19 downturn and avoid both bankruptcies and full-blown restructurings. ...more
8/5/2021
/ Analytics ,
Borrowers ,
Commercial Bankruptcy ,
Coronavirus/COVID-19 ,
Corporate Restructuring ,
Covenant Lite Deals ,
Debt ,
Financial Crisis ,
Leveraged Finance ,
Leveraged Loans ,
Private Equity ,
Relief Measures ,
S&P